The KCNH3 inhibitor ASP2905 shows potential in the treatment of attention deficit/hyperactivity disorder

• Shinji Takahashi ,

  Roles Investigation, Writing – original draft

  * E-mail: shinji-takahashi@astellas.com

  Affiliation Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan

  http://orcid.org/0000-0003-1613-1382

  ⨯
• Makoto Ohmiya,

  Roles Investigation, Writing – review & editing

  Affiliation Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan

  ⨯
• Sokichi Honda,

  Roles Investigation, Writing – review & editing

  Affiliation Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan

  ⨯
• Keni Ni

  Roles Supervision

  Affiliation Drug Discovery Research, Astellas Pharma Inc., Tsukuba, Ibaraki, Japan

  ⨯